LOS ANGELES--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (KYTHERA) today announced that it has successfully completed two Phase 2 clinical studies demonstrating the efficacy, safety, and tolerability of its lead product candidate, ATX-101, for the reduction of submental (‘under-the-chin’) fat. The two Phase 2, randomized, double-blind, placebo-controlled, dose-ranging studies enrolled a total of 157 patients and were conducted across 10 centers in the United Kingdom, Canada, and Australia. Multiple physician and patient endpoints were evaluated.
